澳大利亚悉尼威斯特米德医院（Westmead Hospital）进行的 (18)F-FDG PET-CT 扫描对 Merkel 细胞癌分期和管理的影响。
The impact of (18)F-FDG PET-CT scanning for staging and management of Merkel cell carcinoma: results from Westmead Hospital, Sydney, Australia.
机构信息
Department of Nuclear Medicine & Ultrasound, Westmead Hospital, Westmead, Sydney, Australia.
Department of Nuclear Medicine & Ultrasound, Westmead Hospital, Westmead, Sydney, Australia; Centre for Biomedical Imaging, Research & Development, Westmead Hospital, Westmead, Sydney, Australia; University of Sydney, Sydney, Australia.
出版信息
J Am Acad Dermatol. 2010 Jan;62(1):76-84. doi: 10.1016/j.jaad.2009.06.021.
BACKGROUND
Merkel cell carcinoma (MCC) is a rare cutaneous malignancy with high mortality. Positron emission tomography (PET) using (18)F-fluorodeoxyglucose (FDG) has been shown to be valuable in the management of many types of cancer, and the purpose of this work was to determine its utility for patients with MCC.
OBJECTIVE
We sought to evaluate the impact of (18)F-FDG PET with simultaneous computed tomography (PET-CT) on the staging and management of patients with MCC.
METHODS
We reviewed the medical records of 18 patients with MCC who underwent 21 PET-CT scans at our institution from 2006 to 2008. The impact of PET-CT on staging and management plans were evaluated.
RESULTS
There were 12 men and 6 women with median age of 79 years (range, 54 to 85 years). All proven sites of MCC greater than 5 mm were positive on PET-CT with average maximum standardized uptake values (SUV max) of 4 in primary lesions, 5.6 in nodal disease and 11.5 in distant metastases. PET-CT contributed to altered staging in 7 patients (33%) and a change in management in 9 patients (43%). Two patients were found to have a second primary malignancy, but this did not alter management.
LIMITATIONS
This was a retrospective review. Most patients had stage II or III disease, suggesting some potential referral bias.
CONCLUSIONS
(18)F-FDG PET-CT had a high impact in the management of MCC patients in our series and this investigation merits further assessment.
背景
默克尔细胞癌（MCC）是一种罕见的皮肤恶性肿瘤，死亡率高。正电子发射断层扫描（PET）使用（18）F-氟脱氧葡萄糖（FDG）已被证明对许多类型的癌症的治疗具有重要价值，本研究旨在确定其在 MCC 患者中的应用价值。
目的
我们旨在评估（18）F-FDG PET 与计算机断层扫描（PET-CT）同时进行对 MCC 患者分期和治疗计划的影响。
方法
我们回顾了 2006 年至 2008 年在我院接受 21 次 PET-CT 扫描的 18 例 MCC 患者的病历。评估了 PET-CT 对分期和治疗计划的影响。
结果
患者包括 12 名男性和 6 名女性，中位年龄为 79 岁（范围，54-85 岁）。所有大于 5mm 的 MCC 已知病灶在 PET-CT 上均为阳性，原发灶的平均最大标准化摄取值（SUV max）为 4，淋巴结疾病为 5.6，远处转移灶为 11.5。PET-CT 改变了 7 例患者（33%）的分期，改变了 9 例患者（43%）的治疗方案。2 例患者发现第二原发恶性肿瘤，但这并未改变治疗方案。
局限性
这是一项回顾性研究。大多数患者患有 II 期或 III 期疾病，提示存在一定的潜在转诊偏倚。
结论
（18）F-FDG PET-CT 在我们的研究中对 MCC 患者的治疗具有重要影响，值得进一步评估。
Zotero 插件